Cyrus Harmon
Can fully shutting down the estrogen receptor make a difference in breast cancer? Olema scores $54M to find out in the clinic
From tamoxifen to aromatase inhibitors to fulvestrant, there’s been no lack of endocrine treatments targeted at estrogen receptor-positive breast cancer. But Olema Oncology believes there’s room for more.
The San Francisco-based biotech has convinced investors to pour in $54 million to prove it.
“We saw the need for a drug that could more fully shut down the estrogen receptor,” Cyrus Harmon told Endpoints News. “We call it a complete estrogen antagonist to distinguish from other compounds.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
